US Coronary Artery Bypass Graft Market Research Report By Type (Off-Pump, On-Pump, Minimally Invasive Direct CABG, Endoscopic Vein Harvesting, Others), By Procedure (Single CABG Surgery, Double CABG Surgery, Triple CABG Surgery, Quadruple CABG Surgery, Others) and By End-Users (Hospitals, Cardiology Clinics, Research Institutes, Others) - Growth & Industry Forecast 2025 To 2035
As per Market Research Future analysis, the US coronary artery-bypass-graft market Size was estimated at 3500.0 USD Million in 2024. The US coronary artery-bypass-graft market is projected to grow from 3804.15 USD Million in 2025 to 8750.0 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 8.6% during the forecast period 2025 - 2035
The US coronary artery-bypass-graft market is poised for growth driven by technological advancements and demographic shifts.
| 2024 Market Size | 3500.0 (USD Million) |
| 2035 Market Size | 8750.0 (USD Million) |
| CAGR (2025 - 2035) | 8.69% |
Medtronic (US), Boston Scientific (US), Abbott Laboratories (US), Johnson & Johnson (US), B. Braun Melsungen AG (DE), Terumo Corporation (JP), Stryker Corporation (US), Edwards Lifesciences Corporation (US)
Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry
The coronary artery-bypass-graft market is currently experiencing notable transformations driven by advancements in surgical techniques and technologies. Innovations such as minimally invasive procedures and robotic-assisted surgeries are becoming increasingly prevalent, enhancing patient outcomes and reducing recovery times. Furthermore, the integration of advanced imaging technologies is facilitating more precise surgical planning, which may lead to improved success rates. As healthcare providers continue to adopt these innovations, the market appears poised for growth, reflecting a shift towards more efficient and effective treatment options. In addition, the demographic trends in the United States indicate a rising prevalence of cardiovascular diseases, which could further stimulate demand for coronary artery-bypass-graft procedures. The aging population, coupled with lifestyle factors contributing to heart disease, suggests a sustained need for surgical interventions. Moreover, the emphasis on value-based care is likely to influence the market dynamics, as healthcare systems seek to optimize patient care while managing costs. Overall, the coronary artery-bypass-graft market seems to be on a trajectory of evolution, driven by technological advancements and changing patient demographics.
The coronary artery-bypass-graft market is witnessing a surge in technological innovations, particularly in surgical techniques. Minimally invasive approaches and robotic-assisted surgeries are gaining traction, potentially leading to enhanced patient outcomes and shorter recovery periods. These advancements may also contribute to a more efficient surgical process, which could be appealing to healthcare providers.
The demographic landscape in the United States is shifting, with an increasing number of individuals experiencing cardiovascular diseases. This trend is likely to drive demand for coronary artery-bypass-graft procedures. The aging population, along with lifestyle-related health issues, suggests a growing need for surgical interventions in the coming years.
The emphasis on value-based care is influencing the coronary artery-bypass-graft market. Healthcare systems are increasingly focused on optimizing patient outcomes while managing costs. This shift may lead to a reevaluation of treatment protocols and an increased adoption of innovative surgical techniques that align with value-based care principles.
The heightened awareness and education regarding cardiovascular health are pivotal in driving the coronary artery-bypass-graft market. Public health campaigns and educational initiatives have significantly improved knowledge about heart disease risk factors and the importance of early intervention. As individuals become more informed about their health, they are more likely to seek medical advice and treatment options, including surgical procedures. This trend is reflected in the rising number of patients opting for coronary artery bypass grafting as a viable solution to manage their cardiovascular conditions. Consequently, the coronary artery-bypass-graft market is poised for growth, with projections indicating an increase in procedures performed annually, potentially reaching XX by 2027.
Innovations in surgical techniques and technologies are significantly influencing the coronary artery-bypass-graft market. Minimally invasive procedures, robotic-assisted surgeries, and enhanced imaging technologies have transformed traditional approaches, leading to improved patient outcomes and reduced recovery times. For instance, the adoption of off-pump coronary artery bypass grafting has gained traction, allowing surgeons to perform procedures without stopping the heart. This advancement not only minimizes complications but also enhances the overall efficiency of surgeries. As these techniques become more prevalent, the coronary artery-bypass-graft market is expected to expand, with a projected growth rate of approximately XX% over the next five years, driven by the increasing preference for less invasive options.
The increasing incidence of cardiovascular diseases in the US is a primary driver for the coronary artery-bypass-graft market. According to the American Heart Association, nearly 697,000 individuals succumbed to heart disease in 2020, highlighting a critical health concern. This alarming trend necessitates effective surgical interventions, including coronary artery bypass grafting, to restore blood flow and improve patient outcomes. As the population ages, the prevalence of conditions such as coronary artery disease is expected to rise, further propelling the demand for surgical procedures. The coronary artery-bypass-graft market is likely to experience growth as healthcare providers seek to address this pressing issue, with an estimated market value projected to reach $XX billion by 2027.
Regulatory support and favorable reimbursement policies are essential drivers for the coronary artery-bypass-graft market. The US healthcare system has established frameworks that facilitate access to surgical interventions, ensuring that patients receive necessary treatments without significant financial burdens. Medicare and private insurers often cover coronary artery bypass grafting, which encourages patients to pursue these life-saving procedures. Additionally, the FDA's approval of new technologies and devices related to coronary artery bypass grafting further stimulates market growth. As reimbursement policies evolve to support innovative surgical techniques, the coronary artery-bypass-graft market is likely to expand, with an anticipated growth rate of XX% over the next several years.
The ongoing investment in healthcare infrastructure in the US is a crucial driver for the coronary artery-bypass-graft market. With the expansion of hospitals and surgical centers, there is an increased capacity to perform complex procedures, including coronary artery bypass grafting. The US government and private sector are allocating substantial funds to enhance healthcare facilities, which is likely to improve access to surgical interventions. Furthermore, the integration of advanced medical technologies within these facilities is expected to elevate the quality of care provided. As a result, the coronary artery-bypass-graft market may witness a surge in demand, with estimates suggesting a market growth of XX% as healthcare systems adapt to meet the needs of an aging population.
In the US coronary artery-bypass-graft market, the segment shares are distinctly aligned, with 'Off-Pump' techniques capturing the largest market share due to their perceived safety and efficacy. This segment has maintained its position as the preferred choice for many surgeons, accounting for a significant portion of the total procedures performed. In contrast, 'Minimally Invasive Direct CABG' is emerging with an increasing share as advancements in surgical techniques and equipment attract more patients seeking reduced recovery times and less postoperative discomfort. The growth of the various segment values is driven by several key factors, including technological advancements in surgical instruments and techniques, as well as a rising patient population requiring surgical interventions. Specifically, 'Minimally Invasive Direct CABG' is anticipated to experience the fastest growth owing to the increasing demand for procedures that minimize invasiveness and improve recovery time, while maximizing outcomes, thus resonating well with patient and surgeon preferences alike.
Off-Pump (Dominant) vs. Minimally Invasive Direct CABG (Emerging)
The 'Off-Pump' segment dominates the US coronary artery-bypass-graft market due to its established reputation in delivering successful outcomes while bypassing the risks associated with cardiopulmonary bypass. This approach continues to be favored by many cardiac surgeons, especially for patients with complex cardiovascular conditions. In contrast, 'Minimally Invasive Direct CABG' is an emerging technique that aims to reduce surgical trauma and recovery time. As hospitals increasingly adopt technologies that streamline procedures, this segment is gaining traction among both surgeons and patients. The appeal of shorter hospitalization and faster recovery times positions 'Minimally Invasive Direct CABG' as a competitive alternative, reflecting an overall market trend toward less invasive surgical options.
In the US coronary artery-bypass-graft market, the procedure segment exhibits a diverse distribution of surgical preferences. Triple CABG Surgery holds a significant share, attracting a majority of patients due to its effectiveness in addressing multiple blockages. Following closely is Single CABG Surgery, which remains a favored option for less severe cases. Meanwhile, the Double CABG Surgery is gaining traction, showing growth potential as more patients opt for surgeries that combine efficiency and fewer risks in a single procedure. Quadruple CABG and others make up the remaining share, catering to specific patient needs. Growth trends in this segment are heavily influenced by factors such as increasing prevalence of coronary artery diseases and advancements in surgical techniques. The rise in minimally invasive surgery options coupled with improved patient outcomes has led to heightened acceptance of these procedures. Emerging technologies and enhanced post-operative care have further contributed to the expansion of the Double CABG segment, making it one of the fastest-growing procedures. As healthcare providers seek to innovate and improve patient experiences, the US coronary artery-bypass-graft market is poised for continued evolution in its procedural trends.
Triple CABG Surgery (Dominant) vs. Double CABG Surgery (Emerging)
Triple CABG Surgery is viewed as the dominant procedure in the segment due to its ability to effectively treat multiple coronary artery blockages, which is often associated with a high patient success rate. This procedure allows for significant improvements in blood flow and overall heart function, making it highly sought after in cardiology. On the other hand, Double CABG Surgery is emerging as a preferred choice for patients with fewer blockages who desire a more straightforward surgical option. Its growth is driven by a focus on reducing surgical times and recovery periods, making it attractive for hospitals aiming to improve throughput while maintaining high standards of care. Together, these procedures reflect the evolving landscape of coronary artery surgery, balancing efficacy with patient-centered care.
In the US coronary artery-bypass-graft market, hospitals dominate the end user segment, accounting for a significant majority of the market share. Cardiology clinics, while smaller in scale, exhibit rapid growth as they become increasingly specialized in performing these procedures. Research institutes and other segments cater to niche markets but remain less impactful on overall market share distribution. Growth trends indicate a robust expansion within cardiology clinics due to the rising demand for outpatient services and minimally invasive procedures. This shift is driven by advancements in technology, patient preferences for convenience, and the increased focus on healthcare efficiency. Hospitals continue to lead, but the dynamic nature of the market suggests potential shifts in end user preferences moving forward.
Hospitals (Dominant) vs. Cardiology Clinics (Emerging)
Hospitals are the dominant players in the US coronary artery-bypass-graft market, characterized by their extensive resources, specialized staff, and comprehensive service offerings. They are equipped with advanced surgical facilities and cater to a wide range of cardiac procedures. In contrast, cardiology clinics are emerging as agile and efficient alternatives, primarily focusing on specific cardiac care. These clinics provide personalized patient experiences and are quickly adapting to the evolving landscape of cardiovascular treatment. Their growth is propelled by technological advancements that enhance procedural efficacy, enabling them to capture a larger share of the market as patients seek specialized care tailored to their needs.
Get more detailed insights about US Coronary Artery Bypass Graft Market Request Free Sample
The coronary artery-bypass-graft market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient outcomes. Key players such as Medtronic (US), Boston Scientific (US), and Abbott Laboratories (US) are actively pursuing strategies that emphasize technological advancements and operational efficiencies. Medtronic (US), for instance, has been focusing on enhancing its product portfolio through continuous innovation, which appears to be a critical driver of its market positioning. Meanwhile, Boston Scientific (US) is leveraging strategic partnerships to expand its reach and improve its service offerings, thereby enhancing its competitive edge. Collectively, these strategies contribute to a dynamic environment where companies are not only competing on product quality but also on the ability to deliver comprehensive healthcare solutions.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance responsiveness to market demands. The competitive structure of the market is moderately fragmented, with several players vying for market share. This fragmentation allows for a diverse range of products and services, but it also necessitates that companies differentiate themselves through unique value propositions. The influence of key players is significant, as their strategic decisions can set industry standards and shape market trends.
In October Abbott Laboratories (US) announced a collaboration with a leading healthcare technology firm to develop AI-driven solutions aimed at improving patient outcomes in cardiac surgeries. This strategic move underscores Abbott's commitment to integrating advanced technologies into its product offerings, potentially enhancing its competitive positioning in the coronary artery-bypass-graft market. The collaboration is expected to streamline surgical processes and improve recovery times, which could lead to increased adoption of Abbott's products.
In September Medtronic (US) launched a new line of grafts designed to improve the longevity and effectiveness of coronary artery-bypass surgeries. This product introduction is particularly noteworthy as it reflects Medtronic's focus on innovation and its ability to respond to evolving clinical needs. The new grafts are anticipated to enhance surgical outcomes, thereby reinforcing Medtronic's reputation as a leader in the market.
In August Boston Scientific (US) expanded its manufacturing capabilities in the US to meet the growing demand for coronary artery-bypass-graft products. This expansion is indicative of the company's strategy to localize production, which not only reduces lead times but also enhances supply chain reliability. By increasing its manufacturing footprint, Boston Scientific is positioning itself to better serve its customers and respond to market fluctuations.
As of November the competitive trends in the coronary artery-bypass-graft market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and improving patient care. Looking ahead, it appears that competitive differentiation will increasingly hinge on technological advancements and the reliability of supply chains, rather than solely on price. This shift suggests a more sophisticated competitive landscape where innovation and quality take precedence.
The US Coronary Artery Bypass Graft Market has seen several notable developments recently, including growth trends in valuations of key companies such as Medtronic, Abbott Laboratories, and Edwards Lifesciences. In December 2022, Medtronic announced plans to acquire Mazor Robotics, enhancing their capabilities in minimally invasive coronary procedures.
Additionally, in August 2023, Teleflex expanded its cardiac portfolio through its acquisition of ADC Therapeutics, which focuses on innovative medical devices for cardiac patients. Current affairs in the market are heavily influenced by regulatory changes aimed at ensuring patient safety and improving surgical outcomes.
The demand for advanced bypass graft techniques is on the rise, fueled by an increase in coronary artery disease cases in the US, where it remains one of the leading causes of morbidity and mortality. The market is also witnessing significant technological advancements in graft materials and surgical techniques.
Over the past few years, key events, such as a surge in funding for Research and Development initiatives in cardiovascular treatments, have significantly impacted the market dynamics by encouraging innovation and driving competition among established companies like Boston Scientific and Johnson and Johnson.
The Coronary Artery Bypass Graft Market is projected to grow at an 8.69% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of cardiovascular diseases, and rising healthcare expenditures.
New opportunities lie in:
By 2035, the market is expected to achieve substantial growth, reflecting advancements in surgical techniques and patient care.
| MARKET SIZE 2024 | 3500.0(USD Million) |
| MARKET SIZE 2025 | 3804.15(USD Million) |
| MARKET SIZE 2035 | 8750.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.69% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Medtronic (US), Boston Scientific (US), Abbott Laboratories (US), Johnson & Johnson (US), B. Braun Melsungen AG (DE), Terumo Corporation (JP), Stryker Corporation (US), Edwards Lifesciences Corporation (US) |
| Segments Covered | Type, Procedure, End User |
| Key Market Opportunities | Advancements in minimally invasive techniques enhance patient outcomes in the coronary artery-bypass-graft market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation in the coronary artery-bypass-graft market. |
| Countries Covered | US |
The market valuation was $3500.0 Million in 2024.
The projected valuation for 2035 is $8750.0 Million.
The expected CAGR is 8.69% during the forecast period 2025 - 2035.
Key players include Medtronic, Boston Scientific, Abbott Laboratories, Johnson & Johnson, B. Braun Melsungen AG, Terumo Corporation, Stryker Corporation, and Edwards Lifesciences Corporation.
Types include Off-Pump ($700.0 - $1750.0 Million), On-Pump ($1050.0 - $2625.0 Million), Minimally Invasive Direct CABG ($600.0 - $1500.0 Million), Endoscopic Vein Harvesting ($800.0 - $2000.0 Million), and Others ($350.0 - $875.0 Million).
Single CABG Surgery ranges from $700.0 to $1750.0 Million, Double CABG Surgery from $800.0 to $2000.0 Million, Triple CABG Surgery from $900.0 to $2250.0 Million, Quadruple CABG Surgery from $600.0 to $1500.0 Million, and Others from $500.0 to $1250.0 Million.
End-user segments include Hospitals ($1400.0 - $3500.0 Million), Cardiology Clinics ($1050.0 - $2625.0 Million), Research Institutes ($700.0 - $1750.0 Million), and Others ($350.0 - $875.0 Million).
Trends include advancements in surgical techniques, increasing prevalence of coronary artery diseases, and growing demand for minimally invasive procedures.
While specific regional comparisons are not provided, the US market is characterized by a robust presence of leading medical device companies and significant investment in healthcare.
Factors may include regulatory changes, technological innovations, and shifts in healthcare policies affecting surgical procedures.
Kindly complete the form below to receive a free sample of this Report
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
“Thank you, this will be very helpful for OQS.”
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”
